Agalsidase alfa 3.5mg/3.5ml solution for infusion vials
NHS hospitals in England used £15,212,431 of indicative cost of Agalsidase alfa 3.5mg/3.5ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 15.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Agalsidase alfa 3.5mg/3.5ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Agalsidase alfa 3.5mg/3.5ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £7,939,646 |
| Royal Free London Nhs Foundation Trust | £5,983,458 |
| Manchester University Nhs Ft | £560,668 |
| Cambridge Univ Hosp Nhs Foundation Trust | £456,724 |
| University College London Foundation Tr | £260,385 |
| Univ Hpl B/Ham Nhs Foundation Trust | £11,549 |
The primary-care picture
Agalsidase alfa is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Agalsidase alfa medicine page.